非典型帕金森综合征纹状体突触前多巴胺能功能的影像学荟萃分析
该荟萃分析汇总35项PET或SPECT研究,比较MSA-P、MSA-C、PSP、CBS与PD患者的纹状体突触前多巴胺能功能。结果显示PSP患者尾状核和壳核DAT功能明显低于PD和MSA-P患者,MSA-P患者纹状体DAT功能明显低于MSA-C患者。AADC结果与DAT一致但因数据有限未达显著。
要点
- PSP患者尾状核和壳核DAT功能明显低于PD患者。
- MSA-P患者纹状体DAT功能明显低于MSA-C患者。
- PSP患者纹状体DAT功能明显低于MSA-P患者。
核心结论
- 纹状体突触前DAT功能在PSP患者中明显低于PD和MSA-P患者,在MSA-P患者中明显低于MSA-C患者。
研究设计与样本
- 检索PubMed从建库至2018年8月,共识别1711篇文献,纳入35项PET或SPECT研究(29项DAT、6项AADC,无VMAT2研究)。
- 纳入研究比较非典型帕金森综合征患者与另一诊断组(PD、MSA、PSP或CBS),共包括356例MSA-P、204例PSP、79例CBS和62例MSA-C患者。
- 采用I2统计量检验异质性,使用随机效应模型汇总数据,以Hedges g作为组间比较的效应量估计值,并按PRISMA指南报告结果。
主要发现
- PSP与PD比较:尾状核DAT功能差异34.1%(g=-1.08,95%CI -1.52至-0.64),壳核差异18.2%(g=-0.86,95%CI -1.50至-0.21)。
- PSP与MSA-P比较:纹状体DAT功能差异31.4%(g=-0.70,95%CI -1.21至-0.19)。
- MSA-P与MSA-C比较:纹状体DAT功能差异46.0%(g=1.46,95%CI 0.23至2.68)。
- AADC结果与DAT发现平行,但因数据有限未达显著。
关键数值与推荐
- PSP患者尾状核DAT功能较PD患者低34.1%(g=-1.08,95%CI -1.52至-0.64)。
- PSP患者壳核DAT功能较PD患者低18.2%(g=-0.86,95%CI -1.50至-0.21)。
- PSP患者纹状体DAT功能较MSA-P患者低31.4%(g=-0.70,95%CI -1.21至-0.19)。
- MSA-P患者纹状体DAT功能较MSA-C患者低46.0%(g=1.46,95%CI 0.23至2.68)。
临床怎么用
- 纹状体突触前DAT显像可用于鉴别PSP与PD及MSA-P,以及区分MSA-P与MSA-C。
局限性
- AADC结果因数据有限未达显著。
- 未纳入VMAT2研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple-system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS) have signs and symptoms overlapping those of Parkinson disease (PD), complicating their clinical diagnosis. Although presynaptic dopaminergic brain imaging with PET and SPECT is clinically widely used for patients with suspected PD, the benefit of functional imaging in atypical parkinsonism syndromes remains unclear. We compared striatal presynaptic dopaminergic function in MSA parkinsonism variant (MSA-P), MSA cerebellar variant (MSA-C), PSP, CBS, and PD using combined quantitative data from all published studies. Methods: The PubMed database was searched from inception to August 2018 for the terms "dopamine" OR "dopaminergic" AND "PET" OR "SPECT" OR "SPET" and keywords related to PD, MSA, PSP, and CBS. In total, 1,711 publications were identified. PET or SPECT studies comparing patients with atypical parkinsonism to another diagnostic group (PD, MSA, PSP, or CBS) were included. Tracers for dopamine transporter (DAT), aromatic amino acid decarboxylase (AADC), or vesicular monoamine type 2 were investigated. Tracer binding data were extracted from the original articles. Heterogeneity of the data was examined using I2 statistics, and a random-effects model was used to summarize data. Hedges g was used as an estimator of effect size in group comparisons. Results are reported according to PRISMA guidelines. Results: Thirty-five studies (29 DAT, 6 AADC, no vesicular monoamine type 2 studies) with 356 MSA-P patients, 204 PSP patients, 79 CBS patients, and 62 MSA-C patients were included in the metaanalysis. Caudate nucleus and putamen DAT function was clearly lower in PSP than in PD (caudate: 34.1% difference, g = -1.08, 95% confidence interval [CI] = -1.52 to -0.64; putamen: 18.2%, g = -0.86, 95% CI = -1.50 to -0.21) and MSA-P (striatum: 31.4%, g = -0.70, 95% CI = -1.21 to -0.19) and was clearly lower in MSA-P than in MSA-C (striatum: 46.0%, g = 1.46, 95% CI = 0.23 to 2.68). Although not significant because of limited data, aromatic l-AADC results paralleled the DAT findings. Conclusion: Striatal presynaptic DAT function is clearly lower in PSP patients than in PD and MSA-P patients and is clearly lower in MSA-P patients than in MSA-C patients.
引用
- Kaasinen V, Kankare T, Joutsa J, et al. Presynaptic Striatal Dopaminergic Function in Atypical Parkinsonism: A Metaanalysis of Imaging Studies. J Nucl Med. 2019. PMID: 30979821. doi:10.2967/jnumed.119.227140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。